VVOS
Vivos Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.19
+6.76%Year over year
Reported trailing growth
- Revenue
- +45.2%
- EBITDA
- -71.5%
- EBIT
- -58.5%
- EPS
- -9.6%
- Free cash flow
- -17.4%
- Operating cash flow
- -18.8%
Forward estimates
Based on analyst estimates
- Revenue
- +15.1%
- EBITDA
- -15.3%
- EPS
- +17.3%
Three-year CAGR
- Revenue
- +2.9%
- EBITDA
- -88.7%
- EBIT
- -78.1%
- Net income
- -90.6%
- EPS
- +7.2%
- Free cash flow
- -32.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026